HPV gene chip as well as preparation method and application thereof

Abstract

The invention discloses an HPV gene chip. The gene chip can be individually or simultaneously perform accurate detection, screening and typing on one or more HPV subtypes, can have human genome beta globin and an HPV primer amplification quality control point to monitor the whole detection process and thus being capable of having high sensitivity and specificity. The invention also discloses a preparation method of the HPV gene chip. By utilizing PCR reversal point hybridization method to screen a probe with strong specificity and optimizing the concentration of a spotting probe of the HPV gene chip, the quality and the efficiency of hybridization are improved; and in addition, the gene chip with good optimized condition is further verified with a clinical sample. The HPV gene chip provided by the invention has a better clinical application prospect.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to an HPV gene chip and its preparation method and application. Background technique [0002] Cervical cancer is one of the most common malignant tumors in women, and its incidence rate accounts for the fourth among female tumors in the world. According to statistics in recent years, cervical cancer patients in my country are getting younger and younger, and their morbidity and mortality are still at a high level. Therefore, early screening of cervical precancerous lesions has a great effect on the prevention of cervical cancer. , which has caused researchers to attach great importance to early screening of cervical cancer. In 1983, German scientist Hausen put forward the theory that HPV is the cause of cervical cancer. Since then, many domestic and foreign researchers have done a lot of research on the relationship between cervical cancer and HPV infection, and have made a lot ...

AI Technical Summary

Problems solved by technology

Fluorescence in situ hybridization can locate and have a low false positive rate, but its detection sensitivity is low, the operation is cumbersome, time-consuming and labor-intensive, and it is not suitable for the screening of large-throughput clinical samples

In 1999, hybrid capture second-generation technology (HCⅡ) was approved for HPV detection. This technology was launched by Digene Corporation of the United States. It was the first to be approved by the U.S. Food and Drug Administration (FDA) and is the most widely used HPV detection technology in the world. Although HCⅡ detection is specific Good sex and high sensitivity, but HCⅡ cannot be tested for typing, high cost, and has no internal quality control and other defects

In 2011, the US FDA approved the first-line primary screening of Cobas 4800HPV technology, which can qualitatively detect 14 high-risk types of HPV, and has β-globin as an internal quality control, but its detection of HPV types is limited to these 14 high-risk types

In recent years, there are still some shortcomings in the clinical application of HPV detection methods, such as the inability to detect multiple subtypes of HPV at one time, the operation process is cumbersome, the detection cost is high, and it is time-consuming and labor-intensive.

Images